Alteri Wealth LLC Acquires New Shares in AstraZeneca PLC $AZNCF

Alteri Wealth LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,701 shares of the company’s stock, valued at approximately $650,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. L & S Advisors Inc bought a new stake in shares of AstraZeneca in the fourth quarter valued at about $14,863,000. Monetary Management Group Inc. bought a new stake in shares of AstraZeneca in the fourth quarter valued at about $1,097,000. Burling Wealth Partners LLC bought a new stake in shares of AstraZeneca in the fourth quarter valued at about $4,532,000. Hendley & Co. Inc. bought a new position in AstraZeneca in the fourth quarter worth about $11,373,000. Finally, Saranac Partners Ltd bought a new position in AstraZeneca in the third quarter worth about $876,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $187.10 on Wednesday. The company has a 50-day simple moving average of $187.10 and a two-hundred day simple moving average of $185.87. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.